Key facts
- This page summarizes Christopher Reading's Form 4 filing for BIOVIE INC. (BIVI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 22 Feb 2023, 16:47.
Christopher Reading - 16 Feb 2023 Form 4 Insider Report for BIOVIE INC. (BIVI)
- Reporting relationship
- EVP Neuroscience R&D
- Issuer ticker
- BIVI
- Reported as of
- 16 Feb 2023
- Net transaction value
- -$15,153
- SEC form
- 4
- Accepted by SEC
- 22 Feb 2023, 16:47:56 UTC
- Prior SEC filing
- 18 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /S/ CHRIS READING
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Reading filed Form 4 for BIOVIE INC. (BIVI) on 22 Feb 2023.
Change
- Previous filing in this sequence was filed on 18 Jan 2023.
- Current net transaction value: -$15,153.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIVI
transaction
COMMON STOCK
Tax liability
- Transaction value
- $15,153
- Shares
- -2,476
- Change %
- -6.2%
- Price
- $6.12
- Shares after
- 37,148
- Date
- 16 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Transaction code F - Payment of tax liability by withholding securities incident to the receipt